type 2 diabetes – Medxy AI

Tirzepatide’s Efficacy in HFpEF and Obesity: Unraveling Diabetes’ Influence from the SUMMIT Trial

By MedXY 09/17/2025

The SUMMIT trial reveals that tirzepatide improves heart failure outcomes and quality of life in obese HFpEF patients with or without type 2 diabetes, despite attenuated weight loss in diabetic patients.

Clinical Updates Wellness & Lifestyle

Orforglipron: A Promising Oral Small-Molecule GLP-1 Receptor Agonist for Early Type 2 Diabetes and Obesity Management

By MedXY 09/17/2025

Orforglipron demonstrates significant glycemic control and weight reduction benefits in early type 2 diabetes and obesity, with favorable safety and oral administration convenience.

Clinical Updates Wellness & Lifestyle

Early Insulin Sensitization by Tirzepatide in Japanese Patients with Obesity and Type 2 Diabetes: Insights from a Hyperinsulinaemic-Euglycaemic Clamp Study

By MedXY 09/17/2025

A 12-week prospective study demonstrates tirzepatide significantly improves insulin sensitivity in obese Japanese patients with type 2 diabetes, independent of weight loss, as assessed by hyperinsulinaemic-euglycaemic clamp.

Clinical Updates Wellness & Lifestyle

Efficacy and Safety of cAMP-Biased GLP-1 Receptor Agonist Ecnoglutide Versus Dulaglutide in Type 2 Diabetes: Insights from the EECOH-2 Phase 3 Trial and Broader Clinical Context

By MedXY 09/17/2025

Ecnoglutide, a novel cAMP-biased GLP-1 receptor agonist, demonstrated non-inferior glycemic control and comparable safety to dulaglutide at 52 weeks in type 2 diabetes patients on metformin, offering a promising new treatment option.

Clinical Updates Wellness & Lifestyle

Enhancing Cognitive Function in Older Adults with Type 2 Diabetes: The Superior Effects of Tai Chi in a Mobile Health Trial

By MedXY 09/17/2025

This randomized controlled trial demonstrates that Tai Chi, combined with wearable device monitoring in a telemedicine model, significantly improves cognitive function and sleep quality in older adults with type 2 diabetes, outperforming fitness walking and usual care.

Clinical Updates Wellness & Lifestyle

Impact of a Multifactorial Diet on ApoC-III, Ectopic Fat, and Beta Cell Function in Type 2 Diabetes: Insights from the MEDEA Study

By MedXY 09/16/2025

The MEDEA randomized trial demonstrated that a multifactorial diet reduces plasma ApoC-III, correlates with decreased liver and pancreatic fat, and improves beta cell function in type 2 diabetes compared to a MUFA-rich diet.

Clinical Updates Wellness & Lifestyle

Timing Matters: Impact of Morning vs Afternoon High-Intensity Exercise on Inflammation and Glucose Control in Type 2 Diabetes

By MedXY 09/16/2025

Afternoon high-intensity interval exercise improves post-exercise blood glucose and reduces inflammation more effectively than morning sessions in type 2 diabetes, highlighting circadian influences on exercise metabolism and benefits of meal timing.

Clinical Updates Wellness & Lifestyle

Mobile Text Messaging Enhances Glycemic and Blood Pressure Control in Adults with Uncontrolled Type 2 Diabetes

By MedXY 09/10/2025

A randomized trial in China shows that a 12-month mobile message-based intervention modestly improves HbA1c and systolic blood pressure in patients with uncontrolled type 2 diabetes, supporting mHealth strategies to manage cardiovascular risks.

Clinical Updates Wellness & Lifestyle

Automated Insulin Delivery in Insulin-Treated Type 2 Diabetes: A Comprehensive Review of Randomized Controlled Trial Evidence and Clinical Implications

By MedXY 09/10/2025

Automated insulin delivery (AID) significantly improves glycemic control in insulin-treated type 2 diabetes, demonstrating greater HbA1c reduction and increased time in target glucose range compared to traditional insulin delivery methods.

Clinical Updates Wellness & Lifestyle

Type 2 Diabetes and Colorectal Cancer: Immune Landscape Shapes Risk and Survival Outcomes

By MedXY 09/08/2025

Type 2 diabetes increases colorectal cancer risk and worsens survival, particularly in tumors with low immune cell infiltration, highlighting the interplay between metabolic and immune factors in cancer progression and prognosis.

Clinical Updates Wellness & Lifestyle

Oral Semaglutide Demonstrates Significant Weight Loss Efficacy in East Asian Adults with Overweight or Obesity: Insights from the OASIS 2 Trial

By MedXY 09/08/2025

The OASIS 2 trial shows oral semaglutide 50 mg significantly reduces body weight in East Asian adults with overweight or obesity, with or without type 2 diabetes, offering a promising therapeutic option with manageable safety profile.

Clinical Updates Wellness & Lifestyle

Cagrilintide-Semaglutide Combination Shows Promising Efficacy for Weight and Glycemic Control in Adults with Type 2 Diabetes and Obesity

By MedXY 09/07/2025

A 68-week phase 3a trial demonstrates that once-weekly cagrilintide-semaglutide significantly reduces body weight and improves glycemic control compared to placebo in adults with overweight or obesity and type 2 diabetes, with good tolerability.

Clinical Updates Wellness & Lifestyle

Consistent Improvement in Walking Function Across Diabetes Profiles with Semaglutide in Peripheral Artery Disease: Lessons from the STRIDE Trial

By MedXY 09/07/2025

The STRIDE trial demonstrates that once-weekly semaglutide significantly enhances walking capacity in patients with symptomatic peripheral artery disease and type 2 diabetes, irrespective of baseline diabetes duration, BMI, HbA1c levels, or diabetes medication use.

Clinical Updates Wellness & Lifestyle

Fruit Juice or Whole Fruit for Breakfast in Type 2 Diabetes? Understanding Blood Sugar Control Challenges

By MedXY 08/25/2025

A recent randomized trial shows that consuming 100% orange juice, whole orange pieces, or a sugar-sweetened beverage with breakfast results in similar acute postprandial glycemic responses in well-controlled type 2 diabetes patients.

Clinical Updates Wellness & Lifestyle

Berberine Ursodeoxycholate (HTD1801): A Promising Oral Therapy for Type 2 Diabetes with Multifaceted Metabolic Benefits

By MedXY 08/24/2025

A phase 2 randomized trial shows berberine ursodeoxycholate (HTD1801) significantly reduces HbA1c and improves liver and cardiometabolic parameters in type 2 diabetes patients inadequately controlled with diet and exercise, with a favorable safety profile.

Clinical Updates Wellness & Lifestyle

Berberine and Cinnamon Synergy: A Promising Adjunct Therapy for Improving Glycemic Control and LDL Cholesterol in Type 2 Diabetes

By MedXY 08/24/2025

A 12-week randomized controlled trial demonstrated that supplementation with berberine plus cinnamon significantly lowers fasting blood sugar, HbA1c, and LDL cholesterol in patients with type 2 diabetes, offering potential for improved cardiometabolic risk management.

Clinical Updates Wellness & Lifestyle

Long-Term Kidney Protection with SGLT2 Inhibitors in Type 2 Diabetes and CKD: Insights from the DARWIN-Renal Study

By MedXY 08/23/2025

A large real-world study shows that SGLT2 inhibitors significantly slow kidney function decline and improve albuminuria compared with other glucose-lowering drugs in type 2 diabetes patients with chronic kidney disease.

Clinical Updates Wellness & Lifestyle

Enhancing Beta-Cell Function and Insulin Sensitivity in Type 2 Diabetes: Insights from Dapagliflozin and Exenatide Combination Therapy

By MedXY 08/23/2025

Dapagliflozin and exenatide independently improve beta-cell function and insulin sensitivity in type 2 diabetes; their combination markedly enhances these effects, suggesting superior glycemic control potential.

Clinical Updates Wellness & Lifestyle

Harnessing Digital Therapeutics to Improve Glycemic Control in Type 2 Diabetes: Insights from the BRIGHT Trial

By MedXY 08/20/2025

The BRIGHT trial evaluates AspyreRx, a digital cognitive behavioral therapy, for enhancing glycemic control in type 2 diabetes patients with residual hyperglycemia on stable medical therapy, focusing on efficacy, safety, and real-world applicability.

Clinical Updates Wellness & Lifestyle

Clinical Therapeutic Value of Curcumin Supplementation in Cardiovascular Disease, Diabetes, Cognitive Function, Aging, and Neurodegenerative Disorders: A Synthesis of Recent Evidence

By MedXY 08/18/2025

Current evidence supports curcumin supplementation for reducing cardiovascular risk factors and preventing type 2 diabetes progression, with emerging potential in cognitive decline and aging-related degenerative diseases.

Clinical Updates Wellness & Lifestyle

Oral Semaglutide in Type 2 Diabetes: Efficacy and Safety with and without SGLT2 Inhibitors from the SOUL Trial

By MedXY 08/17/2025

The SOUL trial demonstrates that oral semaglutide significantly reduces major cardiovascular events in type 2 diabetes patients, independently of concurrent SGLT2 inhibitor use, with a favorable safety profile.

Clinical Updates Wellness & Lifestyle

Semaglutide’s Impact on Cardiovascular Outcomes Across Chronic Kidney Disease Stages in Type 2 Diabetes: Insights from the FLOW Trial

By MedXY 08/16/2025

The FLOW trial demonstrates that semaglutide significantly lowers cardiovascular risks and mortality in type 2 diabetes patients with chronic kidney disease, independently of CKD severity.

Clinical Updates Wellness & Lifestyle

Exploring Combined Finerenone and Empagliflozin Therapy in CKD and Type 2 Diabetes: Baseline Insights from the CONFIDENCE Trial

By MedXY 08/13/2025

The CONFIDENCE trial evaluates whether combining finerenone with empagliflozin more effectively reduces urine albumin-to-creatinine ratio in CKD patients with type 2 diabetes compared to monotherapy, based on baseline characteristics of 818 diverse participants.

Clinical Updates Wellness & Lifestyle

Exploring Auricular Acupressure: A Promising Complementary Intervention for Older Adults with Type 2 Diabetes

By MedXY 08/11/2025

A recent study investigates auricular acupressure's effects on glycemic markers, stress, and sleep quality in older adults with Type 2 diabetes, revealing promising outcomes and potential for nursing interventions.

Clinical Updates Wellness & Lifestyle

Optimal Exercise Order for Glycemic Control in Postmenopausal Women with Type 2 Diabetes

By MedXY 08/11/2025

This article reviews a study examining the effects of aerobic versus resistance exercise execution order on glycemia, blood pressure, and heart rate variability in postmenopausal women with type 2 diabetes, emphasizing clinical implications.

Clinical Updates Wellness & Lifestyle

Sustained Metabolic Benefits of a Remote Ketogenic Nutrition Program in Veterans with Type 2 Diabetes: A 3-Year Observational Study

By MedXY 08/11/2025

A 3-year observational study demonstrates that a remotely delivered ketogenic nutrition program leads to sustained improvements in glycemic control, weight, medication use, and metabolic markers among US veterans with type 2 diabetes.

Clinical Updates Wellness & Lifestyle

Impact of Dapagliflozin on Cognitive Function in Older Adults with Type 2 Diabetes and Mild Cognitive Impairment

By MedXY 08/11/2025

A 36-week study shows that dapagliflozin significantly improves cognitive function and metabolic parameters in middle-aged and older patients with type 2 diabetes and mild cognitive impairment.

Clinical Updates Wellness & Lifestyle

Evaluating the Heart Failure Risk in Type 2 Diabetes: Insights from 1.6 Million People in England

By MedXY 08/11/2025

This study evaluates the risk of ischaemic and non-ischaemic heart failure in over 1.6 million individuals with type 2 diabetes, highlighting critical insights for prevention strategies.

Clinical Updates Wellness & Lifestyle

Once-Weekly Insulin Efsitora: A Paradigm Shift in Initiation of Basal Insulin for Type 2 Diabetes

By MedXY 08/09/2025

Weekly fixed-dose insulin efsitora demonstrated noninferiority to daily glargine in reducing HbA1c in insulin-naïve type 2 diabetes, with fewer hypoglycemic events and simpler dose adjustment.

Clinical Updates Wellness & Lifestyle

Anthocyanin + Prebiotic Fiber for Type 2 Diabetes: A 60‑Day Randomised Trial Shows Improved Glucose and LDL

By MedXY 08/09/2025

A double‑blind RCT of 60 patients with T2DM found a 60‑day supplement of riceberry anthocyanin plus inulin and rice bran reduced fasting glucose, HbA1c, and LDL‑C versus placebo with high adherence and no safety signals.